ObjectiveTo analyze the relation between the age of patients with colorectal cancer and neoadjuvant therapy (NAT) regimen decision-making and outcomes in the current version of the Database from Colorectal Cancer (DACCA). MethodsThe version of DACCA selected for this analysis was updated on January 5, 2022. The patients were enrolled according to the established screening criteria and then assigned to 3 age groups: ≤45, 45–65, and ≥65 years old groups. The differences in the NAT regimen decision-making and changes of symptom, imaging, and cancer markers in these 3 age groups were analyzed. ResultsA total of 4 882 data that met the screened criteria were enrolled. The results of statistical analysis showed that the difference in the constituent ratio of patients chosen NAT strategies among 3 age groups was not statistically significant (χ2=8.885, P=0.180). There was a statistical difference in the constituent ratio of patients chosen combined target drug among 3 age groups (χ2=8.530, P=0.014), it was found that the proportion of the patients with ≤45 years old adopting combined target drug regimen was higher. Although the changes of symptom (H=12.299, P=0.056), image (H=1.775, P=0.412), and cancer markers (H=11.351, P=0.183) had no statistical differences of the 3 age groups after NAT, it was found that the proportions of patients with ≥65 years old with progresses of symptom and imaging changes and elevated cancer markers after NAT were higher, and the proportions of patients with ≤45 years old with complete and partial remissions of symptom and imaging changes and with normal cancer markers after NAT were higher. ConclusionsThrough analysis of DACCA data, it is found that in the selection of NAT strategy for colorectal cancer, the lower age group, the higher proportion of patients adopting combined target drug regimen. Although it is not found that age is related to changes of symptoms, imaging, and cancer markers after NAT, it still shows a trend of better outcomes in younger patients.
ObjectiveTo analyze the relation between educational level of patients with colorectal cancer (CRC) and decision-making and curative effect of neoadjuvant therapy (NAT) in the current version of the Database from Colorectal Cancer (DACCA). MethodsThe eligible CRC patients were collected from June 29, 2022 updated DACCA according to the screening criteria and were assigned into 4 groups according to their educational level, namely, uneducated, primary educated, secondary educated, and tertiary educated. The differences in NAT decision-making, cancer marker change, symptomatic change, gross change, imaging change, and tumor regression grade (TRG) among the CRC patients with different educational levels were compared. ResultsA total of 2 816 data that met the screening criteria were collected, 138 of whom were uneducated, 777 of whom were primary educated, 1 414 of whom were secondary educated, and 487 of whom were tertiary educated. The analysis results revealed that the difference in the composition ratio of patients choosing NAT regimens by educational level was statistically significant (χ2=30.937, P<0.001), which was reflected that the composition ratio of choosing a simple chemotherapy regimen in the uneducated CRC patients was highest, while which of choosing combined targeted therapy regimen in the tertiary educated CRC patients was highest. In terms of treatment outcomes, the composition ratios of changes in cancer markers (H=4.795, P=0.187), symptoms (H=1.722, P=0.632), gross (H=2.524, P=0.471), imaging (H=2.843, P=0.416), and TRG (H=2.346, P=0.504) had no statistical differences. ConclusionsThrough data analysis in DACCA, it is found that the educational level of patients with CRC can affect the choice of NAT scheme. However, it is not found that the educational level is related to the changes in the curative effect of patients with CRC before and after NAT, and further analysis is needed to determine the reasons for this.
ObjectiveBased on the current version of Database from Colorectal Cancer (DACCA), we aimed to analyze the comorbidities and preoperative physical status of colorectal cancer patients.MethodsThe DACCA version selected for this data analysis was updated on May 9, 2019. The data items included: surgical comorbidities and classified by systems, surgical history, pelvic disease history, medical comorbidities, and some important subdivision types, infectious disease status, allergic history, nutrition risk screening 2002 (NRS2002) score, amount of weight loss after illness, anemia, low protein status, preoperative ascites status, preoperative pleural effusion status, immune system disease and immunocompromised status, and preoperative nutritional support. Characteristic analysis was performed on each selected data item.ResultsA total of 6 166 admitted data were filtered from the DACCA database. Among them, surgical comorbidities, surgical history, medical comorbidities, and allergy history had 6 166 admitted data, and weight loss had admitted 4 703. There were 2 923 (47.4%) with surgical comorbidities. According to the system, the most common one was digestive system (2 005, 68.6%), and the least one was skin tissue system (24, 0.8%). There were 4 361 (70.7%) patients without surgical history and 1 805 (29.3%) patients had surgical history. There were 2 397 (38.9%) patients without medical comorbidities and 3 769 (61.1%) had medical comorbidities, of which pneumonia/pulmonary infection/chronic bronchopneumonia/lung indeterminate nodules were the most common(2 330, 37.8%), the least was cerebral infarction (unspecified type, 63, 1.0%). There were 5 813 (94.3%) without allergy history and 353 (5.7%) had allergy history. According to the NRS2002 nutrition screening criteria, the scores ranged from 1 to 7 points, with an average of 1.22 points, which could be classified as non-nutrition risk (5 279, 85.6%, included 1 point of 4 310, 2 points of 969), nutritional risk (887, 14.4%, included 3 points of 415, 4 points of 358, 5 points of 100, 6 points of 12, and 7 points of 2), the result of linear regression analysis of NRS2002 scores with the trend of the year showed that: ŷ=0.000 2x–6.275 8, R2=0.716 2, P<0.001. A total of 2 840 (60.4%) had no weight loss while 1 863 (39.6%) had, and weight loss with the trend of year were analyzed by linear regression analysis: ŷ=0.000 2x–3.956, R2=0.685 7, P<0.001. The number of cases of other physical status and the proportion of valid data were anemia (1 194, 33.1%), preoperative ascites (1829, 51.7%), preoperative pleural effusion (171, 5.7%), hypoproteinemia (1 206, 33.6%), immune system disease and immunocompromised status (495, 56.6%), and nutritional support (824, 25.0%).ConclusionsThrough the analysis of the DACCA database, nearly 1/2 of colorectal cancer surgery patients have surgical comorbidities before surgery, more than 1/2 of the patients have medical comorbidities, and the types of diseases are various. Preoperative nutritional status in patients with colorectal cancer also shows certain characteristics, suggesting the state of preoperative risk. These data will provide a detailed big data basis for future preoperative risk assessment of colorectal cancer.
3.2 腹腔镜左半结肠切除术3.2.1 手术要点 腹腔镜左半结肠切除术的要求往往高过腹腔镜右半结肠切除术，所以，除一套腹腔镜器械外，还应增备一套开腹手术器械，一旦腹腔镜手术中出现难以控制的出血以及必须开腹处理的特殊情况，应毫不犹豫中转开腹手术。......
目的 探讨结直肠癌的外科治疗方法。方法 回顾性分析2000年1月至2005年12月期间211例结直肠癌患者的外科治疗资料。结果 全部患者中术后获5年随访者有71例，Dukes分期A、B及C期患者5年生存者分别为12/12例、20/31例及11/28例; 直肠癌术后随访5年者局部复发率为11.8%(4/34)。扩大根治手术行侧方淋巴结清扫及保护盆腔自主神经手术者15例，其中5例患者有不同程度的性功能障碍，经治疗后有改善; 10例患者有不同程度的排尿功能障碍，均经治疗后痊愈。直肠癌保肛手术占77.2%(61/79)，中低位直肠癌保肛手术占60.7%(17/28)。结论 结直肠癌的治疗应将肿瘤的根治始终放在第1位，结肠癌根治应规范化; 全直肠系膜切除术大大减少了直肠癌手术后的局部复发率; 侧方淋巴结清扫宜选择性开展; 保护盆腔自主神经的手术开展有利于减少膀胱和性功能的损伤; 在不降低根治原则的前提下最大限度地提高保肛率，提高患者的生活质量。
ObjectiveTo analyze the staging methods of colorectal cancer data in the current version of the Database from Colorectal Cancer (DACCA).MethodsThe DACCA version selected for this data analysis was updated at April 16th, 2020. The columns included stage during surgery, comprehensive stage of clinical, pathologic and imaging (cpi comprehensive stage), TNM stage, pathologic T stage, imaging T stage, nerves involvement, pathologic anus stage, clinical anus stage, imaging anus stage, pathologic mesentery stage, clinical mesentery stage, imaging mesentery stage, pathologic N stage, imaging N stage, positive lymph nodes ratio, cancerous nodules, M stage, cancerous emboli, pathologic vessel stage, clinical vessel stage, imaging vessel stage, cancerous contamination, and high-risk factors. Extracted data were statistically analyzed.ResultsThe total number of data medical records (data rows) that met the criteria was 6 474, the valid data of TNM stage was 4 511 (69.7%), the valid data of stage during surgery was 5 684 (87.8%), and the valid data of cpi comprehensive stage was 4 045 (62.5%). 1 540 data (41.6%) were consistent with stage during surgery and TNM stage, and 2 884 data (76.7%) were consistent with cpi comprehensive stage and TNM stage. According to the data of T, N, and M stage, the proportion of patients with pathologic T4a stage was the highest (40.5%), followed by T3 stage (24.8%); the most T4a stage (31.9%) on the image, followed by T4b stage (28.7%). The pathologic N stage with lymph node metastasis was about 41.9% (N1 and N2), and the imaging N stage lymph node metastasis was about 51.4%. There were a total of 4 745 valid data in the M stage (73.3%). There were 4 313 valid data in the nerves involvement (66.7%), suspected involvement and confirmed involvement, were 691 (16.0%) and 253 (5.9%) respectively. The valid data of anal pathology, clinical, and imaging stage were 4 115 (63.6%), 599 (9.3%), and 598 (9.2%), and only 30 (0.7%), 8 (1.3%), and 13 (2.2%) on muscle involvement respectively. The valid data of pathologic, clinical, and imaging mesentery stage were 732 (11.3%), 589 (9.1%), and 592 (9.1%). There were 4 458 (68.9%) valid data of positive lymph nodes ratio, and 2 908 (44.9%) valid data of cancerous nodules. There were 4 286 valid data of cancerous emboli (66.2%). A total of 244 data (41.1%) of increased blood vessels around tumors in the imaging vessel stage, 274 data (46.4%) of that in clinical vessel stage, and only 1 063 (27.7%) of pathologic vessel stage. There were 3 865 valid data (59.7%) of the cancerous contamination, and the proportion of the third level (746/2 753, 27.1%) in the high-risk factors was the highest.ConclusionThrough detailed analysis of the DACCA database, it is hoped that a more complete and accurate evaluation system of tumor severity can be established, and high-risk factors can provide some ideas for judging prognosis.
Hyperthermic intraperitoneal chemotherapy (HIPEC) has been used in clinical setting, and is one of the optional treatment for peritoneal surface tumors. It can be used as adjuvant therapy to prevent peritoneal recurrence after gastric or colorectal cancer resection, or to treat those diseases with peritoneal metastasis alone through cytoreductive surgery +HIPEC or HIPEC alone, based on a multidisciplinary model. The updates of European HIPEC-related clinical trials, GASTRIPEC, GASTRICHIP, PRODIGE 7, PROPHYLOCHIP, COLOPEC, COMBATAC, were reported at the 11th International Workshop on Peritoneal Surface Malignancy. In those trials, there was no definitive result surporting that HIPEC treatment might bring survival benefits to patients with gastric or colorectal cancer. However, long-term follow-up results remain to be seen, and some studies are still recruiting. Although several studies were designed as phase Ⅲ trials, the overall sample size was small-scaled. In addition, in the trials, diagnostic laparoscopy were widely used in gastric or colorectal cancer patients, which was helpful to improve staging accuracy and optimizing treatment strategies. The indications for HIPEC therapy (peritoneal cancer index) and technical issues (duration, temperature, approach, and agents) need further investigate.
目的总结结肠冗长症合并结直肠癌的临床病理特征，并文献复习结肠冗长症与结直肠癌的关系。 方法回顾性分析兰州大学第一医院普外一科2011年1月至2012年12月期间收治的17例结肠冗长症合并结直肠癌患者的临床资料。 结果184例结直肠癌患者中合并结肠冗长症17例（9.24%），合并家族性息肉病恶变2例（1.09%），合并遗传性非息肉病性结直肠癌1例（0.54%），合并炎症性肠病1例（0.54%）。合并结肠冗长症的比例较高（P＜0.05）。其中术前经结肠气钡灌肠检查诊断为结肠冗长症5例，术中诊断为结肠冗长症12例。所有患者均行手术治疗，切除结肠13～80 cm，平均33.8 cm。术后发生肺部感染、切口液化1例，腹水1例，肠瘘1例，骶前感染1例。术后17例患者均获随访，随访时间6～12个月，中位数为10个月。随访期间，1例患者于术后1年出现卵巢转移。 结论结肠冗长症合并顽固性便秘可能是结直肠癌发病的高危因素。